GW Henssler & Associates Ltd. reduced its position in CVS Health Co. (NYSE:CVS) by 0.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 315,581 shares of the pharmacy operator’s stock after selling 865 shares during the quarter. CVS Health makes up about 1.7% of GW Henssler & Associates Ltd.’s portfolio, making the stock its 12th largest position. GW Henssler & Associates Ltd.’s holdings in CVS Health were worth $23,741,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of CVS. ShoreHaven Wealth Partners LLC acquired a new position in CVS Health during the fourth quarter worth $25,000. Jackson Grant Investment Advisers Inc. raised its holdings in shares of CVS Health by 127.8% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 360 shares of the pharmacy operator’s stock valued at $25,000 after purchasing an additional 202 shares during the last quarter. Greenhouse Wealth Management LLC purchased a new stake in shares of CVS Health in the fourth quarter valued at about $26,000. Lederer & Associates Investment Counsel CA purchased a new stake in shares of CVS Health in the first quarter valued at about $30,000. Finally, Reby Advisors LLC purchased a new stake in shares of CVS Health in the fourth quarter valued at about $34,000. 74.21% of the stock is currently owned by institutional investors.
In other news, EVP Thomas M. Moriarty sold 49,211 shares of the business’s stock in a transaction on Friday, March 19th. The shares were sold at an average price of $74.15, for a total transaction of $3,648,995.65. Following the sale, the executive vice president now owns 12,778 shares in the company, valued at approximately $947,488.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Eva C. Boratto sold 18,882 shares of the business’s stock in a transaction on Tuesday, March 16th. The shares were sold at an average price of $74.68, for a total transaction of $1,410,107.76. In the last quarter, insiders sold 583,892 shares of company stock worth $43,918,083. 0.46% of the stock is currently owned by company insiders.
CVS Health (NYSE:CVS) last posted its quarterly earnings results on Tuesday, May 4th. The pharmacy operator reported $2.04 EPS for the quarter, topping the consensus estimate of $1.69 by $0.35. The firm had revenue of $69.10 billion for the quarter, compared to the consensus estimate of $68.33 billion. CVS Health had a net margin of 2.99% and a return on equity of 15.60%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm posted $1.91 earnings per share. Equities analysts anticipate that CVS Health Co. will post 7.43 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Monday, May 3rd. Investors of record on Friday, April 23rd were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.48%. The ex-dividend date was Thursday, April 22nd. CVS Health’s dividend payout ratio (DPR) is currently 28.25%.
Several analysts have recently commented on CVS shares. Truist Securities increased their target price on shares of CVS Health from $80.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, April 20th. Guggenheim restated a “neutral” rating on shares of CVS Health in a report on Tuesday, March 23rd. Truist raised their price objective on shares of CVS Health from $80.00 to $88.00 in a report on Wednesday, April 14th. Jefferies Financial Group upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a report on Friday, January 8th. Finally, Morgan Stanley raised their price objective on shares of CVS Health from $86.00 to $92.00 and gave the company an “overweight” rating in a research report on Tuesday, April 20th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $84.31.
About CVS Health
CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services.
Recommended Story: Current Ratio
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.